Mirati Therapeutics, Inc. Common Stock
MRTX
MRTX was delisted on the 22nd of January, 2024.
72 hedge funds and large institutions have $76.5M invested in Mirati Therapeutics, Inc. Common Stock in 2016 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 28 increasing their positions, 15 reducing their positions, and 13 closing their positions.
87% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 15
31% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 13
6% more funds holding
Funds holding: 68 → 72 (+4)
75% less funds holding in top 10
Funds holding in top 10: 4 → 1 (-3)
78% less capital invested
Capital invested by funds: $350M → $76.5M (-$273M)
97% less call options, than puts
Call options by funds: $4K | Put options by funds: $146K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
+$7.97M |
| 2 |
AH
Aviva Holdings
New Providence,
Bahamas
|
+$7.11M |
| 3 |
Renaissance Technologies
New York
|
+$3.76M |
| 4 |
Millennium Management
New York
|
+$3.13M |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$2.55M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$16.2M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$15.9M |
| 3 |
VAM
Visium Asset Management
New York
|
-$13M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$10.6M |
| 5 |
PA
Perceptive Advisors
New York
|
-$5.84M |
MRTX Hedge Fund Activity: Q2 2016 in Review
72 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Mirati Therapeutics, Inc. Common Stock (MRTX) for Q2 2016, worth a combined $76.5M — down 78% from $350M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new MRTX positions and 13 closed out — a net gain of 4 holders — while 28 added to existing stakes and 15 trimmed.
The largest buyer was Broadfin Capital, adding an estimated $7.97M. The largest seller was Fidelity Investments, cutting an estimated $16.2M.
- 72 institutional investors held Mirati Therapeutics, Inc. Common Stock (MRTX) as of Q2 2016, up from 68 in Q1 2016.
- Funds reported $76.5M of Mirati Therapeutics, Inc. Common Stock stock for Q2 2016, down 78% quarter-over-quarter.
- 17 funds opened new Mirati Therapeutics, Inc. Common Stock positions in Q2 2016 and 13 closed out, a net change of +4 holders.
- The largest Mirati Therapeutics, Inc. Common Stock buyer in Q2 2016 was Broadfin Capital, an estimated $7.97M added.
- The largest Mirati Therapeutics, Inc. Common Stock seller in Q2 2016 was Fidelity Investments, an estimated $16.2M sold.
Based on aggregated 13F filings for Q2 2016.